Form 4: Orchestra BioMed Director Jason Aryeh Receives Significant Equity Awards

Orchestra BioMed Holdings, Inc. Director Jason Aryeh was granted 12,422 restricted stock units and 36,797 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Jason Aryeh, a Director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 12,422 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 24, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock, with a reported acquisition price of $0.
• Additionally, Mr. Aryeh was granted 36,797 stock options with an exercise price of $3.22 per share on the same date.
• Both the RSUs and stock options will vest in a single installment on the earlier of the one-year anniversary of the grant date (June 24, 2025) or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent upon his continuous service.
• Following these transactions, Mr. Aryeh beneficially owns 92,482 shares of Common Stock and 36,797 stock options directly.
• The stock options have an expiration date of June 24, 2035.

Sentiment

Score: 6

Explanation: The filing reports a standard equity award to a director, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests. There are no negative financial implications for the company from this specific filing.

Positives

• The equity awards align the Director's financial interests with those of the shareholders, incentivizing long-term performance.
• The grant of RSUs and stock options is a standard component of director compensation, reflecting ongoing commitment to the company.

Negatives

• No negative aspects are directly indicated by this Form 4 filing, which primarily reports an equity award.

Risks

• The vesting of both RSUs and stock options is subject to the Director's continuous service through the specified vesting dates, meaning the awards could be forfeited if service ceases prematurely.
• The value of the stock options is dependent on the future market price of Orchestra BioMed's Common Stock exceeding the exercise price of $3.22.

Future Outlook

The equity awards, particularly the vesting schedule tied to continuous service, indicate an expectation for Director Jason Aryeh's ongoing involvement and contribution to Orchestra BioMed Holdings, Inc. through at least the 2026 Annual Meeting of Stockholders.

Industry Context

The granting of equity awards such as Restricted Stock Units and stock options to directors is a common practice across publicly traded companies, particularly in the biotechnology and medical device sectors, to attract, retain, and incentivize key leadership by aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The structure of these equity awards, including a mix of RSUs and stock options with service-based vesting, is consistent with typical compensation packages for non-executive directors in the U.S. public market.
• The vesting period of approximately one year is a common approach to ensure continued commitment without overly long lock-up periods for director compensation.
• The exercise price of $3.22 for the stock options is the fair market value on the grant date, which is standard practice for incentive stock options.

Related Party Transactions

• The transaction involves the issuance of equity awards (RSUs and stock options) to Jason Aryeh, a Director of Orchestra BioMed Holdings, Inc., which constitutes a related party transaction as it is a compensation arrangement between the company and a member of its board.

Stakeholder Impact

• Shareholders: The awards align the Director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The awards are part of the compensation structure for the board, which is part of the overall management and governance team.

Next Steps

• The RSUs and stock options are expected to vest on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• Director Jason Aryeh will continue his service on the board of Orchestra BioMed Holdings, Inc.

Key Dates

Keywords

Orchestra BioMed Holdings Inc., OBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Award, Beneficial Ownership